Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine

Abstract

Letter to the Editor Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccineWe report a case of a 48-year-old white female patient with a history of relapsing thrombotic thrombocytopenic purpura (TTP). The patient has been known to our department since 2015 when she was diagnosed for the first time with TTP with a high antibody titer (99 U/mL) against ADAMTS13 (A Disintegrin And MeTalloproteinase with a Thrombo-Spondin type 1 motif, member 13) and very low ADAMTS13 activity (Fluorescent Resonance Energy Transfer [FRET] assay: <3 %, normal range 45-138 %). She was treated with ten plasma-exchange (PEX) procedures and corticosteroids and obtained a complete remission. Her first relapse, in February 2019, presented as ecchymoses and severe thrombocytopenia; she was successfully treated again with seven PEX procedures and steroids. Afterwards, the patient was well and periodic blood cell counts (every 6 months, last check performed in October 2020) were normal. On March 12, 2021 the patient was referred to the emergency room of the city hospital of Mantua for a new onset of ecchymoses on both arms and forearms without any other symptoms or signs. The complete blood count demonstrated mild normocytic anemia (hemoglobin 11.5 g/dL, normal range 12.3-14.5 g/dL), moderate thrombocypenia (platelet count 94 × 10 9 /L, normal range 150− 400 × 10 9 /L), a coagulation profile and renal function within the normal range, and moderately increased lactate dehydrogenase (LDH, 637 UI/L, normal range 150-450 UI/L). On a peripheral blood smear, there were about 10 % schistocytes. ADAMTS13 activity was markedly reduced (FRET assay: <3 %) with a high titer of anti-ADAMTS13 antibodies (88 U/mL). Six days before the TTP relapse (March 6, 2021), the patient had received the second dose of the anti-COVID-19 vaccine produced by Pfizer-BioNTech (the first dose had been administered on February 11, 2021). At hospital admission the molecular search of SARS-COV-2 on nasopharyngeal swab was negative while anti-SARS-COV-2 IgG antibodies were 105 UA/mL (chemiluminescent immunoassay DiaSorin, positive >15 UA/mL). The patient was promptly treated with seven PEX procedures and steroids, with a rapid and excellent response (normalization of platelet count and LDH after the third PEX). This is the first case reported in literature of a TTP relapse following anti-COVID-19 vaccination. Other cases of vaccine-related thrombotic microangiopathies have been described, possibly related to the immune dysregulation and/or complement activation triggered by vaccination, particularly against influenza [1][2][3][4]. Further studies are needed to verify the possible association between microangiopathic thrombotic disorders with an autoimmune pathogenesis and the administration of vaccines against COVID-19. ContributionC.S. and A.A.

Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine

“…Yocum [9] and Sissa [10] reported women with co-morbidities in a similar age group as our patient presenting with similar symptoms within a month of administration of the Ad26.COV2.S and BNT162b2 mRNA vaccines, respectively, indicating the presence of a possible diagnosis of VIPIT that was treated efficiently with plasmapheresis in both cases. Of note, in the latter case involving BNT162b2, the patient suffered from relapse precisely six days after the second dosage of COVID vaccine, just as in our casealthough our patient never had TTP before.…”

Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine

“…Another individual was recently described to experience a relapse of TTP 6 days after receiving the second dose of Pfizer-BioNTech COVID-19 vaccine. 8 However, our patient differs from the previous reported case as she does not have a prior history of TTP. TTP has also been reported to develop after several other types of vaccines, particularly influenza vaccines.…”

First report of a de novo iTTP episode associated with an mRNA‐based anti‐COVID‐19 vaccination

“…2017de BRUIJN et ala case of a relapse of iTTP, 6 days after the second dose of the anti-COVID-19 vaccine BNT162b2 16. Moreover, the UK COVID-19 mRNA Pfizer-BioNTech Vaccine Analysis survey contains five cases of iTTP over a 4-month period, and only one case for the AstraZeneca vaccine, after a combined total of more than 40 million vaccine doses given.…”